Nantahala Capital Management LLC trimmed its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 29.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,654,470 shares of the company's stock after selling 704,671 shares during the quarter. Establishment Labs makes up approximately 3.3% of Nantahala Capital Management LLC's holdings, making the stock its 3rd largest position. Nantahala Capital Management LLC owned 5.91% of Establishment Labs worth $76,221,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in ESTA. Quarry LP acquired a new position in shares of Establishment Labs during the fourth quarter valued at approximately $27,000. R Squared Ltd bought a new position in shares of Establishment Labs in the fourth quarter valued at $36,000. Federated Hermes Inc. lifted its position in shares of Establishment Labs by 3.0% during the 4th quarter. Federated Hermes Inc. now owns 32,720 shares of the company's stock valued at $1,507,000 after acquiring an additional 953 shares during the last quarter. Swiss National Bank grew its holdings in shares of Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Establishment Labs by 32.3% in the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after purchasing an additional 2,000 shares in the last quarter. Institutional investors own 72.91% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts recently commented on ESTA shares. Stephens restated an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a research report on Thursday, March 6th. Needham & Company LLC started coverage on Establishment Labs in a research note on Monday, April 14th. They issued a "hold" rating on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.40.
View Our Latest Report on Establishment Labs
Establishment Labs Stock Performance
ESTA traded up $2.35 on Friday, hitting $33.39. The company had a trading volume of 572,721 shares, compared to its average volume of 460,898. The stock has a market cap of $963.17 million, a price-to-earnings ratio of -12.94 and a beta of 0.77. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The company's fifty day moving average price is $35.67 and its 200 day moving average price is $38.88. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $60.12.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.
Establishment Labs Profile
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading

Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.